

Report

Offspring Gender Ratio and the Rate of Recurrent Spontaneous Miscarriages in Jewish Women at High Risk for Breast/Ovarian Cancer

Inbar Gal,¹ Siegal Sadetzki,^{2,5} Ruth Gershoni-Baruch,^{6,7} Bernice Oberman,² Howard Carp,^{3,5} Moshe Z. Papa,^{4,5} Tal Diestelman-Menachem,¹ Shlomit Eisenberg-Barzilai,¹ and Eitan Friedman^{1,5}

¹Susanne Levy Gertner Oncogenetics Unit, ²Gertner Institute of Epidemiology and Public Health, ³Gynecology Division, and ⁴Surgical Oncology Department, Chaim Sheba Medical Center, Tel-Hashomer, Israel; ⁵Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel; and ⁶Institute of Genetics, Rambam Medical Center, and ⁷Bruce Rappoport Medical School Technion, Haifa, Israel

***BRCA1/BRCA2* germline mutations are associated with an increased breast/ovarian cancer risk. Offspring gender ratios may be skewed against male births in *BRCA1* mutation carriers. In addition, the lack of viable homozygous *BRCA1/BRCA2*-mutation carriers implies that recurrent miscarriages may be associated with homozygous fetuses. Jewish Israeli high-risk women who were tested for being carriers of the predominant *BRCA1/BRCA2* mutations in Jewish high-risk families were analyzed for the sex of offspring and the rate of spontaneous miscarriages. Overall, 817 women participated: 393 *BRCA1/BRCA2*-mutation carriers (229 with breast/ovarian cancer) and 424 high-risk noncarriers (208 with breast/ovarian cancer). No differences between the male-to-female offspring ratios of all study groups were noted. Among mutation carriers, the offspring male-to-female ratio was 0.97 (444:460), and among mutation carriers with cancer it was 0.92 (262:284). Similarly, no offspring gender skewing was noted among high-risk noncarriers, regardless of health status. The rates of three or more spontaneous miscarriages among participants with at least one live birth were 4.37% (15/343) among mutation carriers and 3% (12/401) among high-risk women ($P =$ not significant). In conclusion, the offspring gender ratio is similar in high-risk Jewish families and in the general population. The issue of the rate of recurrent miscarriages in high-risk Jewish women is unresolved.**

Germline mutations in two genes, *BRCA1* (MIM 113705) and *BRCA2* (MIM 600185), are estimated to account for ~80% of all inherited breast and ovarian cancer and <50% of familial site-specific breast cancer (Ford et al. 1994, 1998). In Jewish high-risk individuals of Ashkenazi (East European) decent, three predominant, seemingly founder mutations—185delAG (*BRCA1*), 5382insC (*BRCA1*), and 6174delT (*BRCA2*)—seem to account for a substantial proportion (70%–85%) of germline mutations detected in high-risk families with inherited breast and ovarian cancer, including ~40%–50% of families with site-specific breast cancer, and in ≤2.5% of the general Jewish Ashkenazi population (Berman et al.

1996; Neuhausen et al. 1996, 1998; Roa et al. 1996; Abeliovich et al. 1997; Szabo and King 1997). Notably, other mutations in both *BRCA1* and *BRCA2* are infrequent among Jewish Ashkenazi women at a high risk for cancer (Shiri-Sverdlov et al. 2000; Kauff et al. 2002).

The only well-established phenotype of heterozygous *BRCA1/BRCA2* mutation carriers is an increased risk for breast, ovarian, and, to a lesser extent, other cancers (e.g., pancreatic and prostate) (Ford et al. 1994; Struewing et al. 1997; Breast Cancer Linkage Consortium [BCLC] 1999; Thompson et al. 2002; see also BCLC Web site). A recent report suggested that there is a skewing of offspring gender ratios, favoring female offspring in *BRCA1* mutation carriers and not in *BRCA2* mutation carriers, an observation that seemingly supported the role that *BRCA1* protein plays in X chromosome inactivation (de la Hoya et al. 2003). Another intriguing fact is that no viable homozygous *BRCA* mutation carriers have been established in any species, including human beings (Gowen et al. 1996; Suzuki et al. 1997; Kuschel et al. 2001). On the basis of the carrier rate in

Received February 3, 2004; accepted for publication March 24, 2004; electronically published April 28, 2004.

Address for correspondence and reprints: Dr. Eitan Friedman, Head of the Susanne-Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Genetics, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel. E-mail: eitan.friedman@sheba.health.gov.il

© 2004 by The American Society of Human Genetics. All rights reserved. 0002-9297/2004/7406-0021\$15.00

the general population of the mutations predominant in Jewish populations (0.9% for the 185delAG *BRCA1* mutation and 1.5% for the 6174delT *BRCA2* mutation), the predicted rate of fetuses born to Jewish Ashkenazim being homozygous for one of these two mutations is expected to be between 1 in 20,000 births for 6174delT and 1 in 40,000 births for 185delAG. Taken together, the fact that no homozygous mutation carrier has been reported (Kuschel et al. 2001) and the lack of viable homozygous mutation carriers in animal models (Gowen et al. 1996; Suzuki et al. 1997) led us to hypothesize that a plausible reason for recurrent spontaneous miscarriages among Jewish Ashkenazi women may be fetal homozygosity for the recurring *BRCA1/BRCA2* mutations in this ethnic group.

The aim of this study was to assess the putative effect of being a *BRCA1/BRCA2* germline mutation carrier on offspring gender ratio and on the rate of recurrent spontaneous miscarriages.

Jewish women who were counseled for breast/ovarian cancer risk by the oncogenetics services at the Sheba Medical Center in Tel-Hashomer or at the Institute of Genetics at Rambam Medical Center from January 1, 1999, until December 31, 2002, were eligible. Exclusion criteria were non-Jewish origin and unwillingness to participate. The study participants were subdivided into mutation carriers and noncarriers, and each group was further subdivided into affected (with breast/ovarian cancer) or unaffected.

The study was approved by the institutional review board of both medical centers, and each participant signed a written informed consent. Data regarding offspring gender and reproductive history, along with detailed personal and family history of cancer and demographic data, were collected routinely at counseling. Ethnic origin was ascertained for at least three prior generations, on the basis of the countries of birth of the parents and grandparents. On the basis of personal and family cancer history, "high risk" status was assigned to (1) women who have at least two first-degree relatives with breast cancer, one of whom was diagnosed at <40 years of age, (2) women who have at least one first-degree relative who had ovarian cancer at any age and at least one first-degree relative with breast cancer, and (3) women who have at least two first-degree relatives with breast cancer at any age, one of whom had bilateral breast cancer.

DNA was extracted from peripheral venous leukocytes by use of the PUREGene DNA extraction kit (Gentra Inc.), in accordance with the manufacturer's recommended protocol. Three predominant Jewish mutations were tested: 185delAG and 5382insC in *BRCA1* and 6174delT in *BRCA2*. Mutation analysis schemes were based on PCR and restriction enzyme digests that

distinguish the wild type from the mutant allele, as described elsewhere (Rohlf's et al. 1997).

Categorical variables were compared with the use of χ^2 tests, and continuous variables were compared using *t*-tests, adjusting for the effect of birth cohort when necessary. All statistical analyses were performed using S-Plus (S-Plus 2000 Professional Release 3, Insightful Corp.).

Overall, 817 women participated in this study, and 393 were carriers of one of the predominant Jewish mutations in *BRCA1* (185delAG, $n = 195$; 5382InsC, $n = 69$) or in *BRCA2* (6174delT, $n = 129$). Of the 393 carriers, 169 were diagnosed with breast cancer, 47 with ovarian cancer, and 13 with both cancer types. Of the 424 noncarriers, 192 were diagnosed with breast cancer, 13 with ovarian cancer, and 4 with both cancer types. Study participants represent 82.6% of the total 989 women who were eligible for this study.

In both mutation carriers and noncarriers, the mean age of unaffected women was significantly younger than the mean age of women diagnosed with cancer ($P = 0$) (table 1). The mean age at counseling in the noncarrier group was significantly older than that of the carriers ($P = .0001$) (table 1). Yet, the mean age at counseling in all groups ranged from 44.4 to 53.6 years, which are considered to be ages at which the reproductive cycle has been completed. The mean age at diagnosis of breast cancer was 43.2 ± 8.9 years for carriers and 48.8 ± 9.8 years for noncarriers ($P = 0$); the mean age at diagnosis of ovarian cancer was 51.4 ± 11.0 years for carriers and 57.5 ± 9.4 years for noncarriers ($P = .04$). The majority of study participants (97.3%), including both carriers and noncarriers, were of Ashkenazi origin, and the rest were of Iraqi origin, of Balkan origin, or born in Israel.

Of the study participants, 91% of the mutation carriers and 95% of the noncarriers gave birth at least once. A statistically significant difference in the mean number of children was noted between carriers (2.33 ± 1.24) and noncarriers (2.51 ± 1.3) ($P = .045$). No significant differences in the distribution of the number of children were noted between affected and unaffected women within each group.

The total number of males born to noncarriers was 542, compared with 522 females (rate ratio 1.038). Among mutation carriers, there were 444 male offspring, compared with 460 female offspring (rate ratio 0.965). Analysis of offspring gender ratio by specific mutation type shows that there were 215 boys and 219 girls (rate ratio 0.98) among 185delAG *BRCA1* mutation carriers, 71 boys and 84 girls (rate ratio 0.84) among 5382InsC *BRCA1* mutation carriers, and 158 boys and 157 girls (rate ratio 1.006) among 6174delT *BRCA2* mutation carriers. Combined analyses of all *BRCA1* carriers (185delAG and 5382InsC) showed that there were 286 male and 303 female offspring (rate ratio

Table 1

Demographic and Parity-Related Variables by Study Group

VARIABLE	VALUE FOR										P FOR CARRIERS VS. NONCARRIERS
	Carriers					Noncarriers					
	Total	Unaffected	With Breast/Ovarian Cancer	P	Total	Unaffected	With Breast/Ovarian Cancer	P			
N	393	164	229		424	216	208				
Age (years):											
N	390	162	228		422	215	207				
Mean ±SD	48.11 ± 11.15	44.38 ± 10.75	50.75 ± 1.69	0	51.17 ± 11.6	48.79 ± 11.01	53.65 ± 11.7	0			.0001
Range	17-86	17-71	29-86		23-87	25-87	23-86				
Origin:											
N	387	161	226		423	215	208				
Ashkenazi	376 (97%)	155 (96%)	221 (98%)		419 (99%)	213 (99%)	206 (99%)				
Iran/Iraq	3	2	1		2	2	0				
Yemen	0	0	0		1	0	1				
Balkan	2	0	2		1	0	1				
Israeli-born	6	4	2	.28	0	0	0	.26			
No. of live births:											
N	387 (100%)	159 (100%)	228 (100%)		424 (100%)	216 (100%)	208 (100%)				
0	33 (9%)	13 (8%)	20 (9%)		22 (5%)	15 (7%)	7 (3%)				
1	40 (10%)	22 (14%)	18 (8%)		44 (10%)	19 (9%)	25 (12%)				
2	150 (39%)	63 (40%)	87 (38%)		144 (34%)	73 (34%)	71 (34%)				
3	117 (30%)	44 (28%)	73 (32%)		156 (37%)	81 (38%)	75 (36%)				
4	35 (9%)	14 (9%)	21 (9%)		44 (10%)	21 (10%)	23 (11%)				
5+	12 (3%)	3 (2%)	9 (4%)	.39	14 (3%)	7 (3%)	7 (3%)	.56			.18
Mean ±SD	2.33 ± 1.24	2.23 ± 1.2	2.4 ± 1.3	.18	2.5 ± 1.3	2.49 ± 1.3	2.53 ± 1.27	.73			.045
No. of miscarriages ^a :											
N	343 (100%)	144 (100%)	199 (100%)		401 (100%)	200 (100%)	201 (100%)				
0	230 (67%)	100 (69%)	130 (65%)		283 (71%)	136 (68%)	147 (73%)				
1	74 (22%)	30 (21%)	44 (22%)		79 (20%)	41 (21%)	38 (19%)				
2	24 (7%)	12 (8%)	12 (6%)		27 (7%)	17 (9%)	10 (5%)				
3+	15 (4%)	2 (1%)	13 (7%)	.11	12 (3%)	6 (3%)	6 (3%)	.5			.65
Mean ±SD	.52 ± .94	.41 ± .70	.59 ± 1.08	.079	.44 ± .87	.50 ± .95	.39 ± .79	.19			.274
Male-to-female offspring ratio:											
All	444:460 (.98)				542:522 (1.038)						
BRCA1	286:303 (.943)										
185delAG	215:219 (.98)										
5382InsC	71:84 (.84)										
BRCA2	158:157 (1.006)										

^a Number of spontaneous miscarriages among women who have had at least one live birth.

0.943). The differences in rate ratios between all groups (by specific mutation and by *BRCA1* clustering) are statistically insignificant (table 1).

Of the study participants who had been pregnant at some time in their life ($n = 343$ and $n = 401$ among mutation carriers and noncarriers, respectively), 231 reported having at least one spontaneous miscarriage: 113 (33%) of the carriers and 118 (30%) of the noncarriers ($P = .34$). In terms of unaffected women only, there were 44 carriers (31%) and 64 noncarriers (33%) who reported having at least one spontaneous miscarriage ($P = .87$). Among mutation carriers who had been pregnant, 15 (4.37%) had three or more spontaneous miscarriages (2 unaffected women and 13 women with breast/ovarian cancer, $P = .11$), and, among noncarrier women who had been pregnant, there were 12 women (3%) with three or more spontaneous miscarriages, evenly distributed among affected and unaffected individuals ($P = .5$). The mean number of spontaneous abortions for women who had been pregnant was 0.41 ± 0.7 for unaffected mutation carriers and 0.50 ± 0.95 for noncarriers ($P = .8$).

Among mutation carriers, though the mean rate of spontaneous miscarriages was higher among affected women, compared with asymptomatic mutation carriers, the difference was of borderline significance statistically ($P = .079$). However, these differences could not be shown when stratification for age at counseling was performed.

In this study, no apparent differences in male-to-female offspring ratio were noted in Jewish women who are *BRCA1* or *BRCA2* mutation carriers, and the offspring gender ratio was within that reported for the general Western world populations, -1.06 (Davis et al. 1998). In Israel, the male-to-female ratios were 1.059 (70,173:66,217) in 2000 and 1.045 (71,318:68,217) in 2002 (Central Bureau of Statistics 2001, 2003). In the present study, for high-risk noncarriers, the ratios were also within those of the general population, regardless of disease status. Our data differ from those in a recent report on Spanish *BRCA1*-mutation carriers: in that study, a two-fold excess of female offspring was noted in *BRCA1* mutation carriers (de la Hoya et al. 2003). Notably, among the Spanish mutation carriers, there were three families who are carriers of the 185delAG *BRCA1* mutation. In these three families, the ratio of male to female offspring was 0.533 (24:45). By contrast, in the present study, which encompassed 195 185delAG-mutation carriers, representing 174 independent families, there were 215 boys and 219 girls—a male-to-female ratio of 0.981. The reasons for the inconsistent results in terms of the effect of *BRCA1* mutation on offspring gender ratio in both studies may be attributed to several factors, and the difference in sample size may be the single most important factor. Additionally, the

number of families analyzed herein is larger than the number of families analyzed in the Spanish study, and, therefore, our observations are independent of other confounding familial variables. Alternatively, the precise location of gene mutations may affect the resulting protein function, with respect to its putative role in X chromosome inactivation. Another possibility is that there are other genetic factors that control offspring gender ratio in the Spanish population and are in association with *BRCA1* mutations (either genetically or functionally) but are nonexistent in the Jewish Ashkenazi population. The need to assess these factors in a larger study is apparent.

No differences with regard to the rate of recurrent spontaneous miscarriages among all study groups were shown. However, the finding that the rate of recurrent spontaneous miscarriages among all subsets of study participants was higher than that reported for the average risk population (.8%–1%) (Stirrat 1990; Katz and Kuller 1994; Bick et al. 1998) is intriguing, but should be interpreted very cautiously. The often-quoted reference numbers for recurrent (≥ 3) miscarriages in the general population (.8%–1%) are based on historical, non-Israeli controls (Alberman 1988; Bick et al. 1998). In addition, in the study by Roman et al. (1978), which analyzes the data set that is most often cited, there were no women who were pregnant >4 times, whereas, in the present study, all but one of the women who had ≥ 3 spontaneous miscarriages were pregnant at least 5 times. Thus, comparison of the literature-based historical data on non-Jewish women with the current data is invalid. However, given the biological plausibility that *BRCA1/BRCA2* proteins are involved in determining fetal outcome (Gowen et al. 1996; Suzuki et al. 1997), the need for a larger study that will compare spontaneous miscarriage rates among mutation carriers and high-risk women with the rates among an ethnically matched, average-risk population is obvious. This preliminary observation, if confirmed, may signify that, in genetically homogeneous populations with a limited repertoire of mutations in *BRCA1/BRCA2*, the study of recurrent miscarriages should include testing for germline mutations in both genes, especially if there is a suggestive family history.

The limitations of this study should be pointed out. The study population was highly selected for a personal and family history of breast/ovarian cancer. Therefore, the carriers do not represent the total carrier population, and the noncarriers do not represent the general Israeli population. The effect of this inherent limitation on offspring gender ratio is minimal, in all likelihood, since the results were compared within each group and with valid reliable data derived from the Israeli population. Another drawback of the study is the significant age differences among the four subsets of analyzed groups,

though the mean ages of all groups were beyond the reproductive period. Although the younger age of mutation carriers, affected and unaffected, may result in a lower number of live births, this fact by itself could not have a significant effect on offspring gender ratio.

We conclude that among Jewish women at high risk for developing breast/ovarian cancer, either because of family history or by virtue of being *BRCA1/BRCA2* mutation carriers, there is no skewing of offspring gender ratio. The issue of the rate of recurrent spontaneous miscarriages among Jewish *BRCA1/BRCA2* mutation carriers and high-risk women is yet to be resolved by analysis of an appropriate control group.

Acknowledgments

This work was supported partially by a grant from the Middle East Cancer Consortium to Eitan Friedman. This work was performed in part to fulfill the obligations of Inbar Gal for her master's thesis at the Department of Human Genetics, Sackler School of Medicine, Tel-Aviv University, Israel.

Electronic-Database Information

URLs for data presented herein are as follows:

BCLC, <http://www.humgen.nl/lab-devilee/BCLC/statbite.htm>
Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/>

References

- Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in *BRCA1* and 6174delT in *BRCA2* appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. *Am J Hum Genet* 60:505–514
- Alberman E (1988) The epidemiology of repeated abortion. In: Beard RW, Sharp F (eds) *Early pregnancy loss: mechanisms and treatment*. RCOG, London, pp 9–17
- Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK (1996) Two distinct origins of a common *BRCA1* mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. *Am J Hum Genet* 58:1166–1176
- Bick RL, Madden J, Heller KB, Toofanian A (1998) Recurrent miscarriage: causes, evaluation, and treatment. *Medscape Womens Health* 3:2
- Breast Cancer Linkage Consortium (1999) Cancer risks in *BRCA2* mutation carriers. *J Natl Cancer Inst* 91:1310–1316
- Davis DL, Gottlieb MB, Stampnitzky JR (1998) Reduced ratio of male to female births in several industrial countries: a sentinel health indicator? *JAMA* 279:1018–1023
- Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in *BRCA1*-mutation carriers: the Breast Cancer Linkage Consortium. *Lancet* 343:692–695
- Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, et al (1998) Genetic heterogeneity and penetrance analysis of the *BRCA1* and *BRCA2* genes in breast cancer families: the Breast Cancer Linkage Consortium. *Am J Hum Genet* 62:676–689
- Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH (1996) *Brca1* deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. *Nat Genet* 12:191–194
- de la Hoya M, Fernandez JM, Tosar A, Godino J, Sanchez de Abajo A, Vidart JA, Perez-Segura P, Diaz-Rubio E, Caldes T (2003) Association between *BRCA1* mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both. *JAMA* 290:929–931
- Katz VL, Kuller JA (1994) Recurrent miscarriage. *Am J Perinatol* 11:386–397
- Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Rapaport B, Frank TS, Nafa K, Ellis NA, Parmigiani G, Offit K (2002) Incidence of non-founder *BRCA1* and *BRCA2* mutations in high risk Ashkenazi breast and ovarian cancer families. *J Med Genet* 39:611–614
- Kuschel B, Gayther SA, Easton DF, Ponder BA, Pharoah PD (2001) Apparent human *BRCA1* knockout caused by mispriming during polymerase chain reaction: implications for genetic testing. *Genes Chromosomes Cancer* 31:96–98
- Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kessel D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE (1996) Haplotype and phenotype analysis of six recurrent *BRCA1* mutations in 61 families: results of an international study. *Am J Hum Genet* 58:271–280
- Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, et al (1998) Haplotype and phenotype analysis of nine recurrent *BRCA2* mutations in 111 families: results of an international study. *Am J Hum Genet* 62:1381–1388
- Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in *BRCA1* and *BRCA2*. *Nat Genet* 14:185–187
- Rohlf EM, Learning WG, Friedman KJ, Couch FJ, Weber BL, Silverman LM (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene *BRCA1* by PCR-mediated site-directed mutagenesis. *Clin Chem* 43:24–29
- Roman E, Doyle P, Beral V, Alberman E, Pharoah P (1978) Fetal loss, gravidity, and pregnancy order. *Early Hum Dev* 2:131–138
- Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haichick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E (2000) Mutational analysis of *BRCA1* and *BRCA2* in Ashkenazi and non-Ashkenazi Jewish women with familial breast cancer. *Hum Mutat* 16:491–501
- Central Bureau of Statistics (2001) Births. In: *Statistical abstract of Israel*, no 52. State of Israel, chapter 3.11
- (2003) Births. In: *Statistical abstract of Israel*, no 54. State of Israel, chapter 3.11
- Stirrat GM (1990) Recurrent miscarriage. II. Clinical associations, causes, and management. *Lancet* 336:728–733
- Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M,

- McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 336:1401–1408
- Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, Mak TW (1997) Brca2 is required for embryonic cellular proliferation in the mouse. *Genes Dev* 11:1242–1252
- Szabo CI, King MC (1997) Population genetics of *BRCA1* and *BRCA2*. *Am J Hum Genet* 60:1013–1020
- Thompson D, Easton DF, Breast Cancer Linkage Consortium (2002) Cancer incidence in BRCA1 mutation carriers. *J Natl Cancer Inst* 94:1358–1365